Clinical Trial Update: A Study of Onartuzumab (MetMAb) in Combination With Tarceva (Erlotinib) in Participants With Met Diagnostic-Positive Non-Small Cell Lung Cancer Who Have Received Chemotherapy For Advanced or Metastatic Disease (MetLung) [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial evaluating onartuzumab in combination with erlotinib (Tarceva) in patients with Met diagnostic-positive non-small cell lung cancer who …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Onartuzumab (onartuzumab)
• Tarceva (erlotinib)

Snippet

Sponsor: Genentech, Inc. | Conditions: Non-Squamous Non-Small Cell Lung Cancer | Phase 3 | Status: COMPLETED